Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Microbix to JV with Hunan Biopharma on $200 Million Flu Facility

publication date: Nov 2, 2009

Microbix has signed a joint venture agreement with the Hunan Biopharmaceutical Co. Ltd., a state-owned enterprise, to construct a very large, $200 million facility dedicated to influenza vaccine production. The facility will be Asia's largest flu plant and the third largest vaccine facility in the world. Microbix and Hunan Biopharma will each own 50% of the JV. Microbix originally announced plans for the JV well over a year ago.  More details...

Stock Symbol: (TSX: MBX)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital